Where are you?
To give you the most accurate information about our products and what we can do for you, we need to direct you to the right site.
Kuros announces management changes
Kuros Biosciences AG announced today the promotion of Dr. Joost de Bruijn to Chief Executive Officer (CEO), effective December 4, 2017. Dr. de Bruijn is co-founder and current managing director of Kuros Biosciences BV (formerly known as Xpand Biotechnology BV), a wholly owned subsidiary of Kuros. Dr. Ivan Cohen-Tanugi has decided to step down as CEO and member of the Board of Directors. Further, Kuros’ founding CEO and current President, Didier Cowling, will retire from the Executive Management team to serve as a senior advisor to the CEO and continue to serve as a Director on the company’s Board.
Schlieren (Zurich), Switzerland, November 16, 2017
During the course of 2017, Kuros has made significant progress with its lead program MagnetOs, a novel synthetic bone graft substitute designed to regenerate bone in the implanted site in the body, which received clearance in the US and in Europe for commercial sale. Currently, the Company is preparing the launch of the product.
Dr. Christian Itin, Chairman of the Board commented: ”We welcome Joost as the new CEO of Kuros and are looking forward to his leadership of the Company. With his intimate knowledge of our key products, and the orthobiologics space, he is very well positioned to take the Company to its next stage. “
Dr. Joost de Bruijn commented: ”I am delighted and honored by the trust of the Board to take on the role of CEO. We have significant opportunities with MagnetOs and KUR-111/KUR-113 to build an outstanding orthobiologics company and, together with the team, I look forward to bringing our products to market and building value for patients and shareholders.”
Dr. Christian Itin added: ”We would like to thank Dr. Ivan Cohen-Tanugi for making progress towards commercial launch during a transitional year highlighted by product approvals and wish him all the best in his future endeavors. Also, the Board would like to thank Didier Cowling for his valued and dedicated service to the Company as its founding CEO and for supporting the Company to reach commercial stage.”
About Joost de Bruijn
Dr. Joost de Bruijn founded Xpand Biotechnology BV in 2005 and was managing director ever since. He holds the positions of Professor of Biomaterials at Queen Mary University of London, UK (since 2004) and Professor of Regenerative Medicine and Entrepreneurship at Twente University, the Netherlands (since 2011). In 2007, he founded Progentix Orthobiology that signed an exclusive development agreement with NuVasive in 2009 for a novel family of calcium phosphate synthetic bone substitutes. Prior to founding Xpand he was Research Director Bone at IsoTis for seven years, during which he specialized in bone tissue engineering technologies that were brought to clinical application. Dr. de Bruijn has more than 20 years of experience in academia and the life science industry. He has published 165 papers in peer-reviewed journals, and is the inventor of 24 patent families. Dr. de Bruijn is scientific editor and reviewer for numerous international biomaterials, tissue engineering and regenerative medicine journals. He received his PhD from Leiden University in 1993.
About Kuros Biosciences AG
Kuros Biosciences is focused on the development of innovative products for tissue repair and regeneration and is located in Schlieren (Zurich), Switzerland and Bilthoven, The Netherlands. The Company is listed according to the International Financial Reporting Standard on the SIX Swiss Exchange under the symbol KURN. Visit www.kurosbio.com for additional information on Kuros, its science and product pipeline.
Forward Looking Statements
This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words “will” or “expect” or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors, Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.
For further information, please contact:
Kuros Biosciences AG
Chief Financial Officer
Tel: +41 44 733 46 46